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ABSTRACT
Introduction. It is estimated that 50% of vaccines produced annu-
ally are wasted because effectivity is dependent on protein structure 
and heat exposure disrupts the intermolecular interactions that 
maintain this structure. Since 90% of vaccines require a temperature-
controlled supply chain, it is necessary to create a cold chain system 
to minimize vaccine waste. We have developed a more sustainable 
technology via the adsorption of Invasion Plasmid Antigen D (IpaD) 
onto mesoporous silica gels, improving the thermal stability of pro-
tein-based therapeutics.
Methods.xThe solution depletion method using UV-Vis was uti-
lized to study the adsorption of IpaD onto silica gels. The silica-IpaD 
complex is heated above the denaturing temperature of the protein 
and then the IpaD is removed using N,N-Dimethyldodecylamine 
N-oxide (LDAO) and their secondary structure is tested using cir-
cular dichroism (CD).
Results. Pore diameter, pore volume and surface area were charac-
terized for seven different silica gels. Silica gels designated as 6389, 
6378, and 6375 had an adsorption percentage above 95% at pore 
volumes of 2.2, 2.8 and 3.8 cm3 mg-1, respectively. CD analyses con-
firmed that the adsorbed IpaD after the heat treatment displayed a 
similar “W” shape CD signal as the native IpaD, indicating the con-
servation of α-helices. In contrast, the unprotected IpaD after being 
exposed to high temperature shows a flat CD signal, demonstrating 
the loss of secondary structure.
Conclusion. We have successfully increased the thermo-tolerance 
for IpaD using mesoporous silica and continue to further optimize 
mesoporous silica’s physiochemical properties to improve adsorption 
and desorption yields. Kans J Med 2020;13(Suppl 2):6-9.
INTRODUCTION
Temperature-sensitive substances composed of proteins, enzymes, 
and antibodies are inherently unstable at ambient temperature 
because they lose their secondary structure and their activity over 
time. This is a particularly sensitive issue for protein-based medica-
tions, such as vaccines, as their storage and handling usually requires 
continuous cold chain transportation (2 to 8°C) to maintain their 
functional properties. Cold chain logistics are expensive and prone 
to disruptions, which often leads to rapid loss of protein potency 
and deactivation, creating serious concerns for global public health.1
Although there have been several efforts to develop successful 
approaches for enhancing the long-term thermal-stability of pro-
teins and vaccines, including pegylation,2 addition of excipients,3,4 
biomineralization5 and nanopatches.6 These methods are unable to 
provide satisfactory thermal stability, while ensuring the delivery in 
a biologically active form at the point of care, particularly in develop-
ing countries. Thus, the development of innovative and cost-effective 
strategies capable of protecting thermo-sensitive substances would 
eliminate the need for an uninterruptible cold chain and help to solve 
one of the most important issues associated with vaccine wastage. 
Such advancement can help to ensure that proper treatment is deliv-
ered safely and efficiently to the patient, from vaccine production to 
the patient bedside.
Silica gels have demonstrated the ability to retain protein structure 
and functionality.7,8 Some of the most relevant advantages of silicas 
in protein adsorption include: high thermal stability, useful porosity 
range for proteins, simple chemistry, mild pH, tunable surface chem-
istry, and encapsulated biomolecular samples that retain high activity.
Shigellosis is a gastrointestinal disease that causes over a million 
deaths annually,9 especially in developing countries and among chil-
dren.10 Shigella flexneri, the bacteria that is responsible for causing 
Shigellosis, is spread through the fecal-oral route and only a very low 
dose is needed for causing an infection.11 S. flexneri is acid-tolerant, 
and once it reaches the large intestines, it is transcytosed through 
M cells.9,12 At this point, the bacteria induces apoptosis in macro-
phages and invades epithelial cells using a type-III secretion system 
(TTSS).13 Invasion plasmid antigen D (IpaD) has a crucial role in 
TTSS, as it controls the secretion of IpaB and IpaC. All three Ipa 
proteins must be released for epithelial cell invasion.14 
Currently, there is no existing vaccine for shigellosis15 despite 
extensive attempts to formulate a vaccine against this bacteria.16,17,18 
This is because previously developed vaccines have shown high reac-
togenicity in human trials.19 IpaD is a promising target for shigellosis 
vaccine development since it has already been demonstrated that 
IpaD antibodies are present in serum from infected patients.20,21 
Circular dichroism (CD) and Fourier transform infrared (FTIR) 
have proven that IpaD is predominantly an alpha-helical protein.13,22 
IpaD has a high thermal stability with denaturing occurring above 
80°C. Approximately 13% of IpaD is made up of serine amino acids,23 
which are able to form hydrogen bonds at the surface of the silica as 
shown in Figure 1. Therefore, it is possible to encapsulate IpaD within 
mesoporous silica and prevent protein denaturation.
METHODS
Adsorption. Silica gel particles were crushed and sifted to a par-
ticle size of 90 - 150 μm. Then 0.7 mL of IpaD in 1xPBS buffer at 
1.5 mg/mL was added to 30 mg of silica. The solution was mixed on 
the ThermoMixer at 950 rpm and 25°C for 20 hours. The samples 
were centrifuged at 14,800 rpm for four minutes at ambient tem-
perature to separate the silica-IpaD complex from the supernatant. 
6This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)
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The solution depletion method was utilized to determine the amount 
of IpaD transferred from the solution into the silica, such that the 
supernatant concentration indirectly determined the proteins 
adsorbed. The concentration of the supernatant was measured at 
280 nm with an IpaD extinction coefficient of 9.48 M-1cm-1 using the 
Nanodrop 2000 UV-Vis spectrophotometer. The supernatant con-
centration was used along with the original concentration of IpaD to 
quantify the adsorption process in Equation 1:
Percent adsorption = (1-(Supernatant IpaD concentration)/
(Inital IpaD concentration))*100 
Figure 1. Hydrogen bonds between IpaD and mesoporous silica. 
Washing. The unbound proteins in the supernatant were extract-
ed by removing the supernatant from the silica-IpaD particles. A 
sample containing 0.6 mL of 1xPBS was added to the silica to remove 
any unattached IpaD trapped within the silica particles. The vials 
were mixed briefly to loosen the unbound proteins then centrifuged 
at 14,800 rpm for four minutes, and the wash supernatant was 
extracted. The washing method was repeated twice, with the excep-
tion that 1xPBS was not added back to the sample vial on the third 
wash. The supernatant of each wash was combined into a single vial, 
and the concentration was measured.
Heating. The samples were then placed on the ThermoMixer at 
95°C for two hours at 950 rpm. The samples were allowed to cool 
down to room temperature for at least 30 minutes. 
Desorption. To detach the proteins from the silica gel, 0.7 mL 
of 10% LDAO was added to each sample. The samples were then 
mixed at 950 rpm and 25°C for 20 hours. Finally, the samples were 
centrifuged at 14,800 rpm for four minutes and the percent IpaD 
desorption was calculated using the equation: 
Percent desorption= ((Mass of desorbed IpaD)/(Mass of IpaD 
on silica after wash))*100
Circular Dichroism. A Jasco J-1500 Circular Dichroism Spec-
trophotometer instrument was used to evaluate the secondary 
structure of chiral protein samples at a temperature of 15°C over a 
wavelength range of 190 - 260 nm. Before CD measurements were 
performed, the samples were diluted to 0.4 mg/mL in 10% LDAO 
which is within the required concentration range of 0.2 - 0.5 mg/mL. 
The nitrogen flowrate was set at 30 SCFH.  A 1 cm pathlength quartz 
cuvettes was cleaned using 2% Hellmanex II solution to remove any 
remaining biological specimen from previous runs. Then the cuvettes 
were thoroughly washed with milliQ water before purging with nitro-
gen to remove remaining moisture. The cuvettes were filled with 250 
μL of sample and placed in the cuvette holder in the instrument. The 
raw data from CD was reported in Q (mdeg). This was converted to 
molar ellipticity to account for the concentration of the sample and 
properties of IpaD using the equation:
θ=(Q∙100∙MW)/(C∙l∙n∙1000)
MW represents the molecular weight of the protein sample and n 
represents the number of amino acids. For IpaD, these values are 
38825.29 Da and 352, respectively. C is the concentration of the 
sample in mg/mL, and it is found at 280 nm using UV-Vis absorbance 
spectrophotometry. The length (l) of the quartz cuvette is 1 cm for the 
J-1500 instrument.
RESULTS
Physiochemical Characterization. The physicochemical prop-
erties of seven mesoporous silica gel materials were characterized to 
generate a “tool box” with a range of physicochemical properties. The 
material selection criteria for the immobilization of IpaD were corre-
lated between the physico-chemical properties of the support (pore 
sizes, volumes and shapes, and surface functional groups) and with 
those of the protein. The physico-chemical properties of selected 
mesoporous silica gel materials used as supports for the protein ther-
mal-stabilization studies are provided in Table 1. The identification 
of the specific silica gels (6360, 6369, 6765, 6389, 6378 and 6395) 
are confidential and a patent application is being prepared for filing.
Table 1. Physicochemical characterization of selected mesopo-
rous silica gel materials. 
CEBC code Average pore diameter (nm)
Accessible pore 
volume (cm3/g)
Accessible surface 
area (m2/g)
6339 17.7 1.41 319.3
6360 3.9 0.07 39.0
6369 8.1 0.30 125.6
6378 36.3 2.87 286.1
6389 24.2 2.18 370.7
6395 30.2 3.78 300.0
6765 15.0 1.28 332.0
Effect of silica pore volume on IpaD percent adsorption.  After 
improving the protocol to adsorb IpaD onto various silica gel materi-
als, the material properties with the most impact on the adsorption 
efficiency of IpaD were investigated. Our results show that the suc-
cessful adsorption of IpaD protein is strongly influenced by the pore 
volume of the silica gel material (Figure 2). We define accessible pore 
volumes as the pores with diameters ≥ 5 nm. 
IpaD secondary structure. To assess whether the adsorption 
into silica-based supports protects the protein against high tempera-
tures, the IpaD adsorbed onto the silica gels was heated to 95ºC for 
2.5 h, desorbed from the support, and then analyzed by CD. Non-
adsorbed (native) IpaD which was not heated was used as control. 
The CD analyses demonstrate that the adsorbed IpaD after the heat 
treatment (and desorption step) displays a similar “W” shape CD 
signal as the native unheated IpaD.
KANSAS JOURNAL of  M E D I C I N E
Figure 2. Average percent of IpaD adsorbed to mesoporous silica gel materials 
as a function of accessible pore volumes (cm3/g).
DISCUSSION
Effect of silica pore volume on IpaD adsorption. The adsorp-
tion of IpaD onto various mesoporous silicas has been hypothesized 
to have similar surface chemistry for all silicas tested. The adsorp-
tion process is governed by electrostatic interactions and hydrogen 
bonding between the hydroxyls on the silica surface and the prop-
erties of the amino acid side chains on IpaD.23 The most abundant 
amino acid in IpaD is serine, which makes up 13% of the structure. 
This creates the potential for a high level of hydrogen bonding 
between serine residues and the silica surface. As shown in Figure 
2, there is a strong correlation between the pore volume of the silica 
gel to the percent of IpaD adsorbed. For example, silica gel 6765 has 
a pore volume of 1.29 cm3/g and adsorbs an average of 92.2% IpaD, 
while silica gel 6360 has a pore volume of 0.20 cm3/g and adsorbs 
an average of 9.7% IpaD. According to Figure 2, silicas with a pore 
volume greater than 1 cm3/g are expected to adsorb more than 90% 
IpaD. The pore diameter of the silica gels followed a similar trend 
to the pore volume. Therefore, silicas with larger pore volumes and 
pore diameters tend to adsorb more IpaD. This indicates that the 
proteins are not only attaching to the surface of the silica, but also 
being adsorbed into the interior of the larger silica pores. IpaD’s ther-
mostability while attached to silica during heating further supports 
the idea that IpaD is confined within the pores during adsorption. 
IpaD secondary structure. The purpose of this study was to 
demonstrate that silica gels improve the thermostability of IpaD. It 
is evident from Figure 3 that the presence of silica during heating 
enables IpaD to maintain its α-helical structure as shown by the 
characteristic “W” curve. The IpaD in solution completely denatures 
during heating, and the IpaD heated on silica has a small decrease in 
molar ellipticity from that of the native IpaD. We hypothesize that 
this decrease in molar ellipticity will not reduce IpaD’s efficacy in a 
vaccine.
The source of the loss in structure for the IpaD heated on silica is 
most likely due to variables other than heating. It has been commonly 
reported that proteins lose some of their conformational structure 
upon adsorption to a solid surface.24,25,26,27 Another possible alterna-
tive for this loss in structure is the effects of LDAO on IpaD. This 
zwitterionic detergent is used at a high concentration to remove IpaD 
from the silica in these studies. One problem is that LDAO increases 
the high tension (HT) voltage due to the high concentration (10% 
LDAO). During CD experimentation, it has been observed that the 
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HT voltage is above the recommended value of 600 V at wavelengths 
below 200 nm. This indicates that the sample is absorbing too much 
light, which means it is overly concentrated. This effect creates noise 
in the CD wavelength range of 190 - 200 nm, which eliminates the 
expected Cotton effect peak at 195 nm that is seen in the native IpaD 
sample. Furthermore, the drop in molar ellipticity in Figure 3 is 
potentially due to the buffer concentration interference with the CD 
signal for the protein. While it is difficult to isolate the effect of LDAO 
on the CD signal from the physical effect of LDAO interactions with 
IpaD, further studies have indicated that LDAO is partially denatur-
ing IpaD during the desorption process.
Figure 3. CD spectra for IpaD heated to 95°C for 150 minutes attached to silica 
gel 6339, native unheated IpaD, and IpaD denatured in PBS solution at 95°C 
for two hours. The blue curve is the average of 10 samples, and the green curve 
is the average of two samples. 
CONCLUSION
This study has successfully characterized the physiochemical 
properties of different silica gels using the BJH method. With these 
physiochemical properties, it was possible to determine the relation-
ship between pore volume and percent adsorption. In general, as pore 
volume increases, percent adsorption also increases. The most sig-
nificant result is that IpaD adsorbed in mesoporous silica has a higher 
thermal stability than unadsorbed IpaD. This was confirmed by the 
characteristic W shape observed by CD, indicating the presence of 
alpha helices even after heat treatment.
Future research will explore alternative desorbing agents that are 
not as harsh as LDAO to reduce the small loss of protein conforma-
tional structure during desorption.  The next steps will include the 
design of a device where a vaccine encapsulated in silica can be mixed 
with the desorbing agent for removing the bound protein and made 
ready for administration to a patient.
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